Multiple myeloma in renal transplant recipients


Cite item

Full Text

Abstract

Severe renal failure (RF) may be the first and only clinical manifestation of multiple myeloma (MM). Occasionally the disease remains long unrecognized and the patients receive renal function replacement therapy, including renal transplantation (RT). To treat MM in renal transplant recipients is a complex medical and ethical problem. The paper presents the authors' experience in treating 3 patients with MM diagnosed after RT and evolving transplant lesion. Various morphological types of grafted kidney lesion were detected. These included fibrillar glomerulonephritis, cast nephropathy, and the latter concurrent with light-chain deposition disease. RF most rapidly progressed in cast nephropathy. The natural history of the disease was unfavorable in all patients; VAD and PAD chemotherapy programs proved to be ineffective. It is concluded that RT should not be performed in patients with extended-stage MM due to the fact that there is a considerable risk for renal transplant lesion and severe infectious complications that may occur during chemotherapy. Blood and urine immunochemical studies should be conducted in all the patients who are to undergo RT.

About the authors

I G Rekhtina

Hematology Research Center, Russian Academy of Medical Sciences, Moscow

Email: rekhtina@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow

L S Biryukova

Hematology Research Center, Russian Academy of Medical Sciences, Moscow

Email: birjurova@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow

V A Varshavsky

I. M. Sechenov Moscow Medical Academy, Moscow

Email: Vavarsh@mmscience.ru
I. M. Sechenov Moscow Medical Academy, Moscow

G P Golitsina

I. M. Sechenov Moscow Medical Academy, Moscow

Email: golicina@mail.ru
I. M. Sechenov Moscow Medical Academy, Moscow

V G Savchenko

Hematology Research Center, Russian Academy of Medical Sciences, Moscow

Hematology Research Center, Russian Academy of Medical Sciences, Moscow

References

  1. Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch. Intern. Med. 1990; 150: 1693-1695.
  2. Knudsen L., Hippe E., Hjorth M. et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. Eur. J. Haematol. 1994; 53: 207-212.
  3. Torra R., Blade J., Cases A. et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br. J. Haematol. 1995; 91: 854-859.
  4. Everly M. J., Everly J. J., Susskind B. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86 (12): 1754-1761.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies